St Andrews University have applied for patent relating to an invention which provides a purified and crystallised form of RmlA and its X-ray
structure. In addition, it also provides a method of selecting agents which
inhibit the enzyme RmlA, such as, providing a model of the active or regulatory
site (s) of RmlA; reviewing the structure of a potential inhibitory agent for at
least one of these sites; analysing the potential interaction of said agent in
said site (s).
This technology may prove to be of substantial benefit to pharmaceutical and
biotechnology companies, to select for anti-microbial compounds for further
development. For example, an anti-bacterial or anti-fungal agent which binds to
an active or regulatory site of RmlA sufficiently tightly to impede the
biosynthesis of rhamnose and thus growth of the micro-organism.